TuHURA Biosciences, Inc.
NASDAQ:HURABiotechnology
+$0.14 today
- Market cap
- $87.31M
- Beta
- 0.01
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$0.52
Volume 0.19M
Average 0.85M
HURA Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
TuHURA Biosciences, Inc.NASDAQ: HURA
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization grows 67.0% year over year
Q1 FY2026 depreciation & amortization of $23.47K rose 67.0% year over year. Sequentially, it rose 4.1% from the prior quarter. Over 3 fiscal years it compounded at -42.4% a year.
Context
- Depreciation & amortization increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 71.27K USD
- Year-over-year change
- -38.9%
- 4-year CAGR
- -34.2%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 71.27K | -38.9% |
| FY2024 | 2024-12-31 | 116.71K | -34.2% |
| FY2023 | 2023-12-31 | 177.38K | -52.5% |
| FY2022 | 2022-12-31 | 373.09K | -2.0% |
| FY2021 | 2021-12-31 | 380.69K | — |
Depreciation & Amortization vs competitors
How HURA compares with its peers on the latest reported figures
- HURA's LTM Mar 2026 depreciation & amortization of $80.68K is the 7th largest of the 9 companies compared; the peer median is $1.94M.
- Over three fiscal years its annual growth of -42.4% compares with a peer median of +10.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $7.38M | -44.0% | +24.3% | 6.0% | |
| LTM Mar 2026 | $4.89M | -22.2% | +22.5% | 32.5% | |
| LTM Mar 2026 | $3.84M | -23.0% | -14.6% | 334.6% | |
| LTM Mar 2026 | $2.99M | -3.9% | -18.4% | — | |
| LTM Mar 2026 | $880K | +391.6% | — | — | |
| LTM Mar 2026 | $251K | -0.8% | -1.0% | — | |
| LTM Mar 2026 | $80.68K | — | -42.4% | — | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | $53K | +130.4% | +136.6% | 0.4% |
| LTM Mar 2026 | $0 | -100.0% | — | 0.0% | |
| Peer median (excluding HURA) | $1.94M | -13.1% | +10.7% | 6.0% | |
Competitors are the stored peer set for HURA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (7.02M) | (9.37M) | (29.32M) | (21.68M) | (30.05M) |
| Depreciation & Amortization | 380.69K | 373.09K | 177.38K | 116.71K | 71.27K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 654.53K | 218.28K | 478.89K | 1.96M | 6.42M |
| Change in Working Capital | (55K) | 1.56M | 486.92K | 3.29M | (3.15M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | 0 | 0 | 0 |
| Other Working Capital | (55K) | 1.56M | 486.92K | 3.29M | (3.15M) |
| Other Non-Cash Items | (527.06K) | (294.07K) | 21M | 1.59M | (924.51K) |
| Operating Cash Flow | (6.56M) | (7.51M) | (11.95M) | (14.73M) | (27.63M) |
| Capital Expenditures | (3.28K) | (232K) | (79.22K) | (57.91K) | (76.08K) |
| Acquisitions (Net) | 0 | 0 | (1.22M) | (5.99M) | (1.26M) |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (3.28K) | (36.28K) | (1.3M) | (6.05M) | (1.34M) |
| Debt Repayment | 294.07K | (350K) | 2.69M | 28.57M | 616.98K |
| Common Stock Issued | 5.6M | 1.9M | 10.58M | 5M | 21.92M |
| Common Stock Repurchased | 0 | 0 | (24.75K) | 0 | 0 |
| Dividends Paid | (8K) | (8K) | (6K) | 0 | (8.36K) |
| Other Financing Activities | 8K | 0 | 0 | (3.8M) | (2.61M) |
| Financing Cash Flow | 7.04M | 16.25M | 2.66M | 29.77M | 19.93M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 477.91K | 8.71M | (10.59M) | 8.99M | (9.04M) |
| Free Cash Flow | (6.57M) | (7.54M) | (12.03M) | (14.79M) | (27.71M) |
TuHURA Biosciences, Inc.
NASDAQ:HURA
Intrinsic Alpha fair value
Locked
Current Price
$1.37
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.